Cancer Biomarkers Explained | XpertPatient Cancer Centers
Cancer Center Resource

What Are Cancer Biomarkers?
A Plain-English Guide

Biomarker tests help your doctor pick the treatment most likely to work for your cancer. Here’s what you need to know — starting from scratch.

Start Here

What Is a Cancer Biomarker?

Think of a biomarker as a clue your cancer leaves behind. It can be a protein, a gene, or a small molecule found in your blood, tissue, or other body fluids. Doctors use these clues to learn specific things about your cancer.

Simple definition: A biomarker is a measurable signal that tells your doctor something important — like what type of cancer you have, how fast it may grow, or which treatment is most likely to work.

Not all cancers of the same type are the same. Two people with breast cancer, for example, can have very different cancers based on their biomarkers. That’s why biomarker testing is such a big deal — it helps your care team choose the treatment that fits your specific cancer, not just any breast cancer.

This is called precision medicine — matching treatment to the unique biology of your tumor. Biomarker testing is how that matching happens.

4 Types of Biomarkers

What Can a Biomarker Tell Your Doctor?

Biomarkers do four different jobs. Here’s what each one means for you.

🔍 Diagnostic Biomarker

Helps confirm that you have cancer and identifies what type or subtype it is. Like a label on the cancer that tells doctors what they’re dealing with.

Example: AFP for liver cancer

📊 Prognostic Biomarker

Tells your doctor how the cancer is likely to behave over time — whether it may grow slowly or quickly, and the chance it might come back. This helps with planning.

Example: Ki-67 in breast cancer

🎯 Predictive Biomarker

This is the most powerful type. It predicts whether a specific treatment — like a targeted drug or immunotherapy — will work for your cancer. It’s like a key that unlocks the right treatment.

Example: HER2 for trastuzumab

📈 Monitoring Biomarker

Tracks how well your treatment is working. If a biomarker level drops, it’s often a sign the treatment is helping. If it rises, your doctor may want to adjust your plan.

Example: PSA during prostate treatment
How Testing Works

How Are Biomarkers Found?

Depending on the cancer and the biomarker, your doctor may use one or more of these tests.

🧬

Tissue Test (Biopsy)

A small sample of your tumor is removed and checked under a microscope or tested in a lab. This is the most common way biomarkers are found.

🩸

Blood Test

Some biomarkers, like PSA or AFP, are found right in your blood. Easy to do — no biopsy needed.

🧪

Gene Sequencing (NGS)

Next-generation sequencing reads the DNA in your cancer cells to find mutations like EGFR or BRCA. Very detailed and covers many genes at once.

💧

Liquid Biopsy

Finds pieces of cancer DNA floating in your bloodstream. Useful when a tissue biopsy is hard to do, or to track cancer over time.

🔬

FISH Test

Looks for specific gene changes using fluorescent “tags” that light up under a special microscope. Often used to confirm HER2 or ALK status.

🧫

Flow Cytometry

Measures proteins on the surface of cells in a blood sample. Commonly used in blood cancers like leukemia and lymphoma.

Cancer Centers

Biomarkers by Cancer Type

🎀

Breast Cancer

Hormone receptors and HER2 status are the most important biomarkers in breast cancer — they shape almost every treatment decision.

Key Biomarkers
EREstrogen Receptor — If your tumor is ER+, it uses estrogen to grow. Hormone-blocking drugs like tamoxifen can stop that.
PRProgesterone Receptor — Similar to ER. Positive results point toward hormone therapy as a treatment option.
HER2HER2/neu — HER2-positive tumors grow faster, but targeted drugs like trastuzumab (Herceptin) work very well against them.
Ki-67Ki-67 — Measures how fast cancer cells are dividing. A high number means faster growth.
BRCA1/2BRCA Genes — Inherited mutations that raise cancer risk. Also important for treatment — PARP inhibitors may help.
📄 Source: ARUP Consult
🔵

Prostate Cancer

PSA is the most widely used cancer blood test in the world. Newer biomarkers are now reducing unnecessary biopsies.

Key Biomarkers
PSAProstate-Specific Antigen — A protein made by prostate cells. Used for screening, diagnosis, and monitoring treatment response.
PCA3PCA3 — Found in urine after a prostate exam. Helps decide if a biopsy is really needed after a high PSA reading.
TMPRSS2-ERGGene Fusion — Found in about half of all prostate cancers. Being studied as a target for new treatments.
ARAndrogen Receptor — Shows if the cancer needs male hormones to grow. Guides use of hormone-blocking therapy.
📄 Source: NIH / PMC
🫁

Lung Cancer

Biomarker testing has transformed lung cancer care — there are now more targeted treatments for lung cancer than almost any other cancer type.

Key Biomarkers
EGFREGFR Mutation — Found in about 15% of lung cancers. Responds well to oral targeted pills like osimertinib.
ALKALK Rearrangement — A gene change that makes the cancer respond to ALK inhibitors like alectinib.
KRASKRAS Mutation — The most common mutation in lung cancer. A new drug, sotorasib, now targets KRAS G12C directly.
PD-L1PD-L1 — A protein that shows how likely immunotherapy (like pembrolizumab) is to work for your cancer.
TP53TP53 — A gene that normally helps prevent cancer. Mutations here are common and carry prognostic meaning.
📄 Source: NIH / PMC
🟡

Bladder Cancer

FGFR3 testing has opened the door to a new targeted treatment option for bladder cancer patients.

Key Biomarkers
FGFR3FGFR3 Mutation — A gene change targeted by erdafitinib, the first FDA-approved targeted therapy for bladder cancer.
TP53TP53 — Mutations in this gene are linked to more aggressive bladder cancers and carry prognostic meaning.
PD-L1PD-L1 — Tested to see if immunotherapy drugs like pembrolizumab or atezolizumab are likely to help.
📄 Source: NIH / PMC
🟢

Colon Cancer

RAS and BRAF mutations and mismatch repair status must be checked before treatment begins — they change which drugs can help.

Key Biomarkers
KRAS/NRASRAS Mutations — If your cancer has these mutations, certain drugs (EGFR inhibitors) will NOT work. This test is always done first.
BRAFBRAF V600E — A mutation that signals more aggressive disease and guides use of a BRAF/MEK inhibitor combo.
MSI-H/dMMRMismatch Repair — About 15% of colon cancers have this. MSI-H tumors respond very well to immunotherapy (pembrolizumab).
📄 Source: NIH / PMC
🟣

Endometrial Cancer

Molecular testing now places endometrial cancers into four groups — and each group has a different recommended treatment path.

Key Biomarkers
PTENPTEN — The most commonly mutated gene in endometrial cancer. Loss of PTEN drives the cancer to grow via a signal pathway called PI3K.
PIK3CAPIK3CA — Another gene in the same pathway. Being studied as a target for new drugs.
MSI-H/dMMRMismatch Repair — About 25% of endometrial cancers are MSI-H, making them good candidates for immunotherapy with pembrolizumab.
📄 Source: NIH / PMC
🟠

Kidney (Renal) Cancer

The VHL gene is the driving force behind most clear cell kidney cancers — and it guides the choice of targeted therapy.

Key Biomarkers
VHLVHL Gene — When VHL is mutated or lost, the cancer gets a signal to create new blood vessels to feed itself. Targeted drugs (VEGF inhibitors) block that signal.
CA9CA9 (Carbonic Anhydrase 9) — A protein that shows up when VHL is lost. Used as a prognostic marker.
PD-L1PD-L1 — Guides whether immunotherapy combinations like nivolumab + ipilimumab are likely to work.
📄 Source: ASCO
🔴

Leukemia

Genetic testing has made leukemia one of the most precisely classified blood cancers. Your specific genetic makeup determines your treatment plan.

Key Biomarkers
BCR-ABL1Philadelphia Chromosome — The defining marker of CML. A targeted drug (imatinib/Gleevec) was designed specifically to block this and changed CML from a deadly disease to a manageable one.
FLT3FLT3 Mutation — Found in AML. Associated with faster-growing disease. Targeted drugs (midostaurin, gilteritinib) are now available.
NPM1NPM1 Mutation — When found in AML without FLT3, it’s actually a more favorable sign — and helps doctors choose treatment intensity.
📄 Source: NIH / NBK
🟤

Liver Cancer

AFP is the oldest and most widely used liver cancer marker — still central to diagnosis and monitoring treatment today.

Key Biomarkers
AFPAlpha-Fetoprotein (AFP) — A protein that is often very high in people with liver cancer. Measured in a simple blood test and used to track how treatment is working.
GPC3Glypican-3 — A protein found on liver cancer cells. Being studied as a marker and potential target for antibody-based treatments.
TP53TP53 — A mutation in this gene is a sign of more aggressive liver cancer and carries a less favorable outlook.
📄 Source: NCI Cancer.gov
⬛

Melanoma

BRAF V600E is one of the most actionable mutations in all of oncology — found in about half of all melanomas.

Key Biomarkers
BRAF V600EBRAF Mutation — Present in ~50% of melanomas. Targeted drugs (vemurafenib, dabrafenib + trametinib) work very well and often cause tumors to shrink quickly.
NRASNRAS Mutation — Found in ~20% of melanomas. Carries a less favorable prognosis; targeted MEK inhibitors are under study.
PD-L1PD-L1 — Helps predict if checkpoint immunotherapy (pembrolizumab, nivolumab) will be effective against your melanoma.
📄 Source: American Cancer Society
🔷

Multiple Myeloma

M protein is the central biomarker of myeloma — tracking it tells your doctor how active the disease is and how well treatment is working.

Key Biomarkers
M ProteinM Protein — An abnormal protein made by myeloma cells and found in blood or urine. The main marker for tracking disease burden and response to treatment.
Beta-2 MicroBeta-2 Microglobulin — A protein in the blood; higher levels indicate more advanced disease. Part of standard myeloma staging.
FLCFree Light Chains — Protein fragments in the blood linked to myeloma activity. Used to diagnose, stage, and monitor response to treatment.
📄 Source: American Cancer Society
🟩

Non-Hodgkin Lymphoma

CD20 status is one of the most powerful biomarkers in cancer — it unlocks access to rituximab, one of medicine’s great success stories.

Key Biomarkers
CD20CD20 — A protein on the surface of B-cells. If your lymphoma is CD20+, targeted drugs like rituximab can attach to it and help destroy the cancer cells.
BCL2BCL2 — A protein that helps cancer cells survive longer than they should. A drug called venetoclax can now target BCL2 directly.
MYCMYC Rearrangement — When MYC is disrupted along with BCL2 (“double hit”), the lymphoma is more aggressive and needs more intensive treatment.
📄 Source: American Cancer Society
🟧

Pancreatic Cancer

BRCA testing has opened an important new treatment door for some pancreatic cancer patients — ask your doctor if you’ve been tested.

Key Biomarkers
CA 19-9CA 19-9 — The main blood marker for pancreatic cancer. Used to help track how the cancer is responding to treatment over time.
KRASKRAS Mutation — Found in over 90% of pancreatic cancers. A key driver mutation and emerging drug target.
BRCA1/2BRCA Genes — About 5–7% of pancreatic cancer patients carry a BRCA mutation. If you do, a drug called olaparib (a PARP inhibitor) may help. Ask about germline testing.
📄 Source: American Cancer Society
🔸

Rectal Cancer

Rectal cancer shares most biomarkers with colon cancer — and MSI-H rectal cancer is now showing some of the most exciting results in all of immunotherapy.

Key Biomarkers
KRAS/NRASRAS Mutations — Must be tested before treatment. These mutations mean EGFR-targeting drugs won’t work and should be avoided.
MSI-H/dMMRMismatch Repair — Very exciting in rectal cancer: recent studies show some MSI-H rectal cancer patients achieve a complete response to immunotherapy alone — meaning no detectable cancer — without surgery.
TP53TP53 — A mutation that tells doctors something about how the cancer is likely to behave over time.
📄 Source: American Cancer Society
Common Questions

Biomarker FAQs

Will my insurance pay for biomarker testing?

Most major insurance plans and Medicare cover biomarker tests when your doctor orders them as part of your cancer care. Coverage has expanded a lot in recent years. Always double-check with your insurance before testing — ask your care team’s billing office for help.

What if my test comes back negative or unclear?

A negative result just means that one treatment target isn’t present — there are still other options. An unclear result may mean your doctor wants to retest or try a different method. Always talk through your results with your oncologist.

Can biomarkers change over time?

Yes. Cancer cells can change and develop new mutations, especially after treatment. That’s why your doctor may repeat testing if your cancer comes back or stops responding. Liquid biopsy makes this easier — it’s just a blood draw.

Should I ask about comprehensive genomic profiling (CGP)?

CGP tests hundreds of biomarkers at once and may find treatment options that individual tests would miss. It’s most often recommended for advanced or hard-to-treat cancers. Ask your oncologist if it’s right for your situation.

What questions should I ask my doctor about biomarkers?

Good ones to start with: “Has my tumor been tested for biomarkers?” / “Which biomarkers are most important for my cancer type?” / “Are there targeted therapies or clinical trials based on my results?” / “Should I have comprehensive genomic profiling?”

Know Your Biomarkers. Own Your Journey.

XpertPatient navigators can help you understand your test results and your options.

Go to XpertPatient.com →

XpertPatient Cancer Centers — Biomarker Resource Guide

This page is for education only. It is not medical advice. Always work with your cancer care team.

Sources: NCI · American Cancer Society · ARUP Consult · ASCO · NIH/PMC · Cancer.gov